MEAMyristoylethanolamide
A saturated fourteen-carbon N-acylethanolamine with no affinity for CB1; an assumed, undemonstrated entourage role.
C₁₆H₃₃NO₂
CAS 142-58-5
- Family
- Endocannabinoid or related mediatorEndocannabinoidome
- Molar mass
- 271.40 g/mol
Updated on
In plain terms
Myristoylethanolamide belongs to the same chemical family as anandamide, but its fatty chain is saturated and it does not bind the cannabis receptors. It is assumed to act indirectly, by occupying the enzymes that destroy anandamide, but this has not been verified for it.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to MEA: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of MEA.
FAAHFAAH found in 7 regions of the body
- CortexpresentCortical pyramidal neurons1
- Basal gangliapresentStriatal neurons1
- HypothalamuspresentPresent in hypothalamic nuclei1
- CerebellumpresentPurkinje cells and cerebellar layers1
- BrainstempresentInferior olivary nuclei1
- Adipose tissuepresentExpressed in mature adipocytes2
- BonepresentPresent on osteoclasts3
Map sources
- Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res, 2002 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- FAAHInhibitorno measured value cited
Class datum, not measured for this molecule: N-acylethanolamines are hydrolysed by FAAH and, for some of them, by NAAA (Tsuboi 2018; Piomelli 2020). No constant has been published for myristoylethanolamide, and the competition with anandamide inferred from it has not been tested
Pharmacology
Myristoylethanolamide is the saturated fourteen-carbon member of the N-acylethanolamine family, the one that counts anandamide among its unsaturated members and palmitoylethanolamide among its best-studied saturated ones. It shares with them the biosynthetic route, through a phospholipid precursor cleaved by NAPE-PLD, as well as the degrading enzymes, FAAH and NAAA (Tsuboi 2018; Piomelli 2020). It does not share their receptor pharmacology: the absence of unsaturations on its chain deprives it of the CB1 affinity that characterises anandamide. Watanabe and colleagues documented this dissociation in 1999 in three mouse models: no saturated ethanolamide, myristoylethanolamide included, produced catalepsy up to 40 mg/kg intravenously, where anandamide acted with a median effective dose of 6.0 mg/kg, and myristoylethanolamide did not prolong pentobarbital-induced sleep; it did, however, cause — like anandamide and its oleoyl and linoleoyl homologues — a significant but small hypothermia, of a few tenths of a degree, at 10 mg/kg. In a series devoted to pain, it had little or no effect on the formalin response, unlike palmitoylethanolamide (Calignano 2001). This profile places it among the entourage lipids rather than the messengers: competition for the enzymes that degrade the active endocannabinoids is plausible given the shared routes, but it has not been tested for this molecule, which carries no cannabinoid effect of its own.
Key sources.
- Watanabe et al. 1999, Biol Pharm Bull: pharmacological effects in mice of anandamide and related fatty acid ethanolamides (new tab)PMID 10328555
- Calignano, La Rana & Piomelli 2001, Eur J Pharmacol: antinociceptive activity of palmitoylethanolamide; myristylethanolamide has no notable effect on formalin (new tab)PMID 11426841
- Piomelli et al. 2020, J Med Chem: N-acylethanolamine acid amidase (NAAA), structure, function and inhibition (new tab)PMID 32191459
- Tsuboi et al. 2018, Inflamm Regen: metabolism of endocannabinoids and N-acylethanolamines (review) (new tab)PMID 30288203
- PubChem CID 8890, N-myristoylethanolamine (identifiers and use classification) (new tab)
History
- Source
- An endogenous compound present in trace amounts in animal tissues, where it is produced by the same enzymatic machinery as the other N-acylethanolamines (Tsuboi 2018). The molecule is also manufactured industrially: as myristamide MEA it is listed as a cosmetic ingredient (opacifier, antistatic agent, viscosity control, foam booster) and as a detergent additive, uses unrelated to its biological function (PubChem CID 8890, use classification).
Biosynthetic pathway
In vivo
The molecule is the saturated fourteen-carbon member of the N-acylethanolamine family, formed from myristic acid. Its production follows the route common to this family: an N-acyl-phosphatidylethanolamine (NAPE) is built by transfer of an acyl chain onto the amine function of a phosphatidylethanolamine, then releases the corresponding ethanolamide under the action of NAPE-PLD, further enzymes of this pathway having been identified more recently; degradation is carried out by FAAH and, for some substrates, by NAAA (Tsuboi 2018). No specific measurement of these steps has been published for myristoylethanolamide.
Legal framework
- European Union
Not controlled. The compound is listed as a cosmetic and industrial ingredient and as such falls under the European cosmetics regulation and chemical registration rules. It is the subject of no marketing authorisation as a medicine.
- France
An endogenous substance, listed neither as a narcotic nor as a psychotropic substance (orders of 22 February 1990), and foreign to the benzo[c]chromene family covered by the ANSM decisions of June 2024. It is legally used as a surfactant ingredient in cosmetics and detergents, within the regulatory framework specific to those products. No health claim is authorised for it.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Endocannabinoid or related mediator › Endocannabinoidome
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
No dedicated article.
References
- Watanabe et al. 1999, Biol Pharm Bull: pharmacological effects in mice of anandamide and related fatty acid ethanolamides (new tab)PMID 10328555
- Calignano, La Rana & Piomelli 2001, Eur J Pharmacol: antinociceptive activity of palmitoylethanolamide; myristylethanolamide has no notable effect on formalin (new tab)PMID 11426841
- Piomelli et al. 2020, J Med Chem: N-acylethanolamine acid amidase (NAAA), structure, function and inhibition (new tab)PMID 32191459
- Tsuboi et al. 2018, Inflamm Regen: metabolism of endocannabinoids and N-acylethanolamines (review) (new tab)PMID 30288203
- PubChem CID 8890, N-myristoylethanolamine (identifiers and use classification) (new tab)
Identifiers
Names
- Common name
- Myristoylethanolamide
- IUPAC name
- N-(2-hydroxyethyl)tetradecanamide
- Other names
- NMEA · N-myristoylethanolamine · 14:0 NAE · myristamide MEA
Identifiers
- Formula
- C₁₆H₃₃NO₂
- CAS
- 142-58-5
- PubChem CID
- 8890(new tab)
- InChIKey
- JHIXEZNTXMFXEK-UHFFFAOYSA-N
- SMILES
- CCCCCCCCCCCCCC(=
O) NCCO
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.